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Edited by Gianni CesareniAbstract The 90-kDa heat shock protein (HSP90) is a molec-
ular chaperone that assists in the folding and assembly of pro-
teins in the cytosol. We previously demonstrated that the
antineoplastic reagent, cisplatin, inhibits the aggregation preven-
tion activity of mammalian HSP90. We now show that cisplatin
binds both the amino terminal and carboxyl terminal domains of
the human HSP90 and diﬀerently aﬀects these two domains. Cis-
platin blocks the aggregation prevention activity of HSP90C,
but not HSP90N. In contrast, cisplatin induces a conformational
change in HSP90N, but not HSP90C. These results indicate
that cisplatin modulates the HSP90 activities through two diﬀer-
ent mechanisms using the two distinct binding sites of the HSP90
molecule.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The 90-kDa heat shock protein (HSP90) is a molecular
chaperone highly conserved from prokaryotes to eukaryotes.
In mammalian cells, HSP90 is the most abundant molecular
chaperone in the cytosol and exerts a variety of essential func-
tions. These functions include aggregation prevention, mainte-
nance, transport, assembly and degradation of client proteins
and are performed through an ATP-dependent conformational
change [1–4].
HSP90 is a multi-domain protein consisting of three do-
mains: the N-terminal ﬂexible domain (HSP90N) that binds
ATP, the middle domain (HSP90M), and the C-terminal do-
main (HSP90C) required for dimerization. The HSP90N and
HSP90C domains are both reported to have aggregation pre-
vention activities [5,6]. Recently, X-ray crystallographic and
electron microscopic analyses revealed that HSP90 undergoes
a large conformational change using these domains during
the ATPase cycle [7,8].
HSP90 associates with a variety of co-chaperones including
the activator of HSP90 ATPase (Aha1) [9], p23 [10] and
HSP90/HSP70-organizing protein (Hop) [11]. These co-chaper-*Corresponding author. Fax: +81 889 3041.
E-mail address: itohh@ipc.akita-u.ac.jp (H. Itoh).
0014-5793/$34.00  2008 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2008.10.029ones activate the ATPase activity of HSP90. Many signaling
protein kinases (e.g., Cdk4, Cdk6 and Raf family kinases) are
stabilized by HSP90 in the presence of Cdc37 [12,13]. HSP90
associates with steroid hormone receptors (e.g., glucocorticoid
receptor, androgen receptor and estrogen receptor) and regu-
lates the transport of these receptors [14,15].During this process,
a multi-chaperone complex containing HSP90, HSP70, Hop,
HSP40, and p23 associates with steroid hormone receptors,
and HSP90 binds HSP70 via the TPR domains of Hop in this
complex [16,17]. Since this complex is abundant in tumor cells,
inhibition of the HSP90 function by antineoplastic agents like
geldanamycin and its derivative, 17-allylamino-17-demethoxy-
geldanamycin (17-AAG), is eﬀective for treating cancers [18].
Cisplatin (cis-diamminedichloroplatinum) is a widely used
antineoplastic drug for clinical cures. Cisplatin possesses the
ability to bind DNA and inhibits the replication of DNA,
thereby it inhibits tumor cell growth [19]. Previously, we found
that cisplatin directly binds HSP90 and inhibits its aggregation
prevention activity in vitro [20]. The cisplatin aﬃnity chroma-
tography of tryptic peptides of HSP90 suggested that there is a
cisplatin binding site in the HSP90C domain. Cisplatin is re-
ported to stimulate the dimer formation of HSP90 and inhibit
the HSP90-dependent activation of the glucocorticoid receptor
in vitro [21]. Since cisplatin inhibits glucocorticoid receptor-
dependent and androgen receptor-dependent transcriptional
activities in a dose-dependent manner in human cultured cells
[22], inhibition of the HSP90 by cisplatin is considered to occur
in vivo as well as in vitro. However, the molecular mechanism
in which cisplatin inhibits the HSP90 activity is largely un-
known.
We analyzed the aggregation prevention activity and confor-
mational change in the puriﬁed recombinant HSP90N and
HSP90C domains in the presence of cisplatin in vitro. Cisplatin
blocked the aggregation prevention activity of HSP90C, but
not HSP90N, whereas this drug induced a conformational
change in HSP90N, but not HSP90C. We will discuss the role
of HSP90N and HSP90C during the cisplatin-dependent inhi-
bition of the HSP90 activities.
2. Materials and methods
2.1. Puriﬁcation of HSP90, HSP90N and HSP90C
Full-length HSP90 was puriﬁed from porcine brain by ammonium
sulfate fractionation, Q-Sepharose and hydroxyapatite column chro-
matography [23]. The amino terminal domain (1–236) or carboxyblished by Elsevier B.V. All rights reserved.
Fig. 1. Cisplatin speciﬁcally binds HSP90N and HSP90C. (A) HSP90
puriﬁed from bovine-brain was applied to cisplatin or transplatin-
aﬃnity columns and washed with 0.15 M NaCl in 10 mM Tris–HCl,
pH 7.4. Proteins were eluted with free cisplatin (3.33 mM) or
transplatin (1.67 mM). Fractions were analyzed by SDS–PAGE (9%
gel) followed by Coomassie brilliant blue staining. (B) Recombinant
human HSP90N or HSP90C domains were applied to cisplatin aﬃnity
column and washed. Proteins were eluted with a linear gradient of
cisplatin (0–3.33 mM). Fractions were analyzed by SDS–PAGE (11%
gel).
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were expressed in Escherichia coli BL21. These domains were puriﬁed
by Ni-aﬃnity column chromatography and dialyzed against 10 mM
Tris–HCl (pH 7.4).
2.2. Cisplatin aﬃnity column chromatography
Cisplatin–sepharose column chromatography was basically carried
out as previously described [20]. HSP90 was applied to a cisplatin–se-
pharose column equilibrated with 10 mM Tris–HCl (pH 7.4) and
washed with 10 column volumes of 10 mM Tris–HCl (pH 7.4) contain-
ing 0.15 M NaCl. The bound proteins were eluted with free cisplatin.
The eluted proteins were analyzed by SDS–PAGE (9% gel) followed
by Coomassie Brilliant Blue staining. Transplatin-aﬃnity column
chromatography was carried out as described above except that trans-
platin (Sigma, St. Louis, MO) was used instead of cisplatin.
2.3. Far-UV circular dichroism (CD)
The CD measurements were performed by a J-720 spectropolarime-
ter (Jasco, Tokyo, Japan). The CD spectrum (190–240 nm) of HSP90N
(1.1 lM) or HSP90C (1.1 lM) in 50 mM HEPES-NaOH buﬀer (pH
7.4) in the presence or absence of cisplatin (11.0 lM) were recorded
at 25 C using a cuvette with a 0.5-mm path length. The observed spe-
ciﬁc ellipticity after normalization against a blank was converted to the
mean residue ellipticity [h] (degrees cm2 dmol1).
2.4. Measurement of protein aggregation
Thermal aggregation of 0.05 lMmitochondrial citrate synthase (CS)
(Roche, Mannheim, Germany) in 10 mM Tris–HCl buﬀer (pH 7.4) at
50 C was monitored by optical density at 500 nm using a Pharmacia
Ultrospec 3000 UV–vis spectrophotometer equipped with a semi-
micro-cuvette (0.5 ml) with a path length of 10 mm and a temperature
control unit. In this study, 1 arbitrary unit denotes the absorbance of
0.15. HSP90, HSP90N or HSP90C (0.05 lM) was added to the CS
solution in the presence or absence of 2 mM cisplatin.
2.5. Protease resistance assay
HSP90, HSP90N, or HSP90C (1.0 lM) was incubated in the pres-
ence of 4.3 nM trypsin in 10 mM Tris–HCl (pH 7.4) at 37 C for
30 min. ATP (5 mM) or cisplatin (2.33 mM) were added to the reaction
to evaluate their eﬀect. After incubation, these samples were analyzed
by SDS–PAGE and Coomassie Brilliant Blue staining.3. Results
3.1. Cisplatin binds both HSP90N and HSP90C
We previously reported that the wild type HSP90 binds cis-
platin as analyzed by cisplatin aﬃnity column chromatography
[20]. This binding was conﬁrmed in the present study with a
control experiment showing that transplatin, a geometric iso-
mer of cisplatin, does not bind HSP90 (Fig. 1A). These results
conﬁrmed that cisplatin speciﬁcally binds to HSP90. We also
previously reported that the C-terminal tryptic fragment of
HSP90 could be puriﬁed by cisplatin aﬃnity chromatography,
suggesting the existence of a cisplatin binding site at the C ter-
minus. To analyze whether cisplatin exclusively binds the C-
terminal domain, we prepared recombinant HSP90N and
HSP90C proteins and carried out cisplatin column chromatog-
raphy (Fig. 1B). The elution patterns indicated that cisplatin
can bind both HSP90N and HSP90C, and suggested that cis-
platin binds HSP90C, slightly more strongly than HSP90N.
3.2. Cisplatin inhibits aggregation prevention activity of
HSP90C, but not HSP90N
HSP90 inhibits CS aggregation and cisplatin blocks the
HSP90-dependent aggregation prevention [20]. To determine
which domain is aﬀected by cisplatin, aggregation prevention
by HSP90N or HSP90C against CS was tested in the presenceof cisplatin. The CS aggregation was inhibited in the presence
of HSP90C and this aggregation prevention eﬀect was signiﬁ-
cantly reduced by the cisplatin (Fig. 2B) although the eﬀect
of cisplatin was slightly weaker than the case of the full-length
HSP90 (Fig. 2A). In contrast, the HSP90N-dependent aggre-
gation prevention was not aﬀected by the presence of cisplatin
(Fig. 2C). These results appear to be consistent with the obser-
vation that cisplatin binds more strongly to HSP90C than
HSP90N. Despite the fact that full-length HSP90 posses the
HSP90N domain that is potentially unable to be inhibited by
cisplatin for aggregation prevention activity, this drug did in-
hibit full-length HSP90. This may due to global conforma-
tional changes in full-length HSP90 (e.g. interaction between
HSP90N and HSP90C) in the presence of cisplatin, because
it induces alteration of secondary structure of HSP90N as
described bellow.
3.3. Cisplatin alters secondary structure of HSP90N, but not
HSP90C
We also previously reported that cisplatin induces changes in
the secondary structures of the full-length HSP90 as deter-
mined by the CD spectrum. To analyze which domain is
responsible for the conformational change, structural changes
in the HSP90N and HSP90C were analyzed by CD measure-
ments in the presence of cisplatin. Intriguingly, HSP90N, but
not HSP90C, underwent structural changes in the presence
of cisplatin (Fig. 3). These results indicate that cisplatin diﬀer-
ently aﬀects the HSP90N and HSP90C.
3.4. Cisplatin induces protease resistance of HSP90N but not
HSP90C
To examine whether the binding of cisplatin to HSP90N and
HSP90C induces conformational changes, the protease resis-
tance was analyzed in the presence and absence of cisplatin
(Fig. 4A). We checked the eﬀect of ATP for protease resistance
Fig. 2. Cisplatin strongly inhibits aggregation prevention activity of
HSP90C, but not of HSP90N. Thermal aggregation of CS (0.05 lM) in
the presence of 0.05 lM HSP90 (square), in the presence of 0.05 lM
HSP90 and 2 mM cisplatin (triangle), or in the absence of both
components (diamond) was monitored by optical density at 500 nm
(mean with standard deviation of three independent experiments). (A)
Full-length HSP90, (B) HSP90C, and (C) HSP90N.
Fig. 3. Cisplatin alters two-dimensional structure of HSP90N, but not
of HSP90C as determined by Far-UV CD spectrum. CD spectrum of
HSP90C (A) and HSP90N (B) were determined in the absence (closed
circle) or presence (open circle) of cisplatin. h denotes mean residue
ellipticity.
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HSP90 (top), HSP90C (middle) and HSP90N (bottom). It isnotable that ATP protects the HSP90C dimerization domain
as well as the HSP90N ATPase domain. This may be due to
the ATP-binding activity of HSP90C as described by Soti et
al. [24]. Under the same conditions, cisplatin stimulated the
protease resistance of the full-length HSP90 and HSP90N,
but not HSP90C (Fig. 4A, compare lanes 2 and 6). Although
bands of the full-length HSP90 became weaker in the presence
of both ATP and cisplatin (Fig. 4A, lanes 7 and 8, top), this is
unlikely to be due to increased protease sensitivity because
large complexes of HSP90 were detected using 2–15% gradient
gel (Fig. 4B, lanes 7 and 8, top). The formation of large com-
plexes of HSP90 is also reported in the simultaneous presence
of geldanamycin and cisplatin [25]. Taken together, these
observations are consistent with the results of the CD measure-
ments, and conﬁrmed that cisplatin induces conformational
changes in HSP90N, but not HSP90C.4. Discussion
In the present study, we found that cisplatin binds both
HSP90N and HSP90C (Fig. 1). Cisplatin inhibits the aggrega-
tion prevention activity of HSP90C, but not HSP90N (Fig. 2),
whereas this drug alters the structure of HSP90N, but not
HSP90C (Figs. 3 and 4). These observations indicate that
HSP90 has two diﬀerent cisplatin binding sites and that cis-
platin diﬀerently aﬀects the HSP90N and HSP90C domains.
Fig. 4. Tryptic cleavage of HSP90 is prevented by the presence of
cisplatin both in amino terminal and carboxyl terminal domains. (A)
Full-length HSP90 (top), HSP90C (middle), or HSP90N (bottom) were
treated with trypsin in the presence of ATP and cisplatin. These
samples were analyzed on SDS–PAGE (11% gel) and stained with
Coomassie brilliant blue. (B) The same samples as used in the lanes 7, 8
of panel A were analyzed by SDS–PAGE using a 2–15% gradient gel.
Note that large complexes of HSP90 are formed in the presence of
ATP and cisplatin. Lane 9, trypsin.
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of HSP90 located in the HSP90N domain [26]. The androgen
and glucocorticoid receptors interact with HSP90 in a multi-
chaperone complex containing HSP70, HSP40, p23 and Hop
[16,17], and this complex activates these receptors in an
ATP-dependent manner [27]. Since both geldanamycin and cis-
platin induce degradation of these receptors in cultured cells
[22], these two drugs appear to have a common eﬀect on the
HSP90 function, since the HSP90N-binding activity found in
the present study may contribute to the common eﬀect of gel-
danamycin and cisplatin.
Geldanamycin induces the degradation of Raf-1 and Akt ki-
nases in vivo. The crystal structure of the HSP90-Cdc37-kinase
complex indicated that Cdc37 binds HSP90 via the HSP90N
domain and the Cdc37 binding site is overlapped with the gel-
danamycin binding site [13], and the geldanamycin derivative,
17AAG, inhibits the HSP90-Cdc37 binding [12]. In contrast,
cisplatin does not induce degradation of Raf-1 and src [22].
These observations suggest that geldanamycin has an eﬀect
distinct from cisplatin against HSP90 at least in part. As cis-
platin has no eﬀect on the HSP90N-dependent prevention
against CS aggregation, the eﬀect of cisplatin on HSP90N
may be speciﬁc to substrates or co-chaperones.
Cisplatin has a synergistic anti-cancer eﬀect when used with
geldanamycin [25]. Since cisplatin binds HSP90C as well as
HSP90N and strongly inhibits the aggregation prevention
activity of HSP90C, but not HSP90N, cisplatin may have dis-
tinct function against HSP90-assisted cellular functions. Thus,the synergistic anti-cancer eﬀect of cisplatin might be mediated
by the HSP90C domain, although this possibility remains to be
investigated. In addition, the existence of multiple cisplatin
binding sites in the HSP90 molecule may facilitate the self-
assembly of HSP90 to a large complex. This may lead to the
formation of non-functional aggregates as observed in the
simultaneous presence of cisplatin and ATP (Fig. 4), or cis-
platin and geldanamycin [25]. Taken together, these observa-
tions suggest that the existence of the cisplatin binding site in
HSP90C, in addition to HSP90N, plays an important role in
the inhibition of the HSP90 functions required for mainte-
nance of essential cellular proteins.References
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